Promising PARP Inhibitor Strategies Emerging in PlatinumSensitive Ovarian Cancer

Promising PARP Inhibitor Strategies Emerging in Platinum-Sensitive Ovarian Cancer

Richard T. Penson, MD, MRCP, discusses novel strategies with PARP inhibitors and the use of biomarkers to create more personalized treatments for patients with platinum-sensitive ovarian cancer.

More From BioPortfolio on "Promising PARP Inhibitor Strategies Emerging in Platinum-Sensitive Ovarian Cancer"